Shares of DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report) have been given an average recommendation of “Moderate Buy” by the six research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $45.25.
DBVT has been the subject of several research reports. Citigroup reissued a “market outperform” rating on shares of DBV Technologies in a research report on Thursday, October 29th. Cantor Fitzgerald restated an “overweight” rating on shares of DBV Technologies in a report on Thursday, September 10th. Citizens Jmp lowered their price objective on shares of DBV Technologies from $55.00 to $47.00 and set a “market outperform” rating on the stock in a report on Thursday, October 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DBV Technologies in a research note on Thursday, October 15th. Finally, Guggenheim reduced their price objective on shares of DBV Technologies from $51.00 to $46.00 and set a “buy” rating for the company in a report on Friday, October 30th.
Check Out Our Latest Analysis on DBV Technologies
DBV Technologies Price Performance
DBV Technologies stock opened at $11.02 on Monday. DBV Technologies has a 12-month low of $8.63 and a 12-month high of $26.18. The firm’s fifty day moving average is $10.84 and its 200 day moving average is $16.40. The company has a market capitalization of $692.94 million, a PE ratio of -3.66 and a beta of -0.84.
DBV Technologies (NASDAQ:DBVT – Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.41). DBV Technologies had a negative net margin of 5,392.17% and a negative return on equity of 120.95%. The company had revenue of $1.60 million during the quarter, compared to the consensus estimate of $0.56 million. Sell-side analysts expect that DBV Technologies will post -2.22 EPS for the current fiscal year.
Hedge Funds Weigh In On DBV Technologies
Several hedge funds have recently modified their holdings of the company. Royal Bank of Canada increased its holdings in DBV Technologies by 167.1% in the 1st quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock worth $98,000 after acquiring an additional 2,928 shares during the last quarter. Cetera Investment Advisers grew its stake in DBV Technologies by 93.4% in the 1st quarter. Cetera Investment Advisers now owns 25,358 shares of the company’s stock valued at $530,000 after buying an additional 12,243 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in DBV Technologies during the 3rd quarter valued at $144,000. Personal CFO Solutions LLC bought a new stake in DBV Technologies during the 1st quarter valued at $264,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of DBV Technologies by 170.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,600 shares of the company’s stock worth $249,000 after acquiring an additional 13,600 shares in the last quarter. Institutional investors own 71.74% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. Founded in France, the company’s research centers on epicutaneous immunotherapy, an approach that delivers small amounts of an allergen through the skin using a patch. Its lead investigational program is Viaskin Peanut, a patch-based treatment being developed for peanut allergy. DBV has also conducted research into treatments for other conditions, including milk allergy and eosinophilic esophagitis.
Recommended Stories
- Five stocks we like better than DBV Technologies
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
